Wall StreetMultiCell Technologies, Inc. (OTC BB: MCET) is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) affect translational control of the immune response through Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development:

  • MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
  • MCT-465, a preclinical synthetic dsRNA therapeutic candidate for the treatment of solid tumor cancers such as those expressing TLR-3.
  • MCT-475, a discovery stage antibody therapeutic candidate used in conjugation with dsRNA for the treatment of solid tumor cancers.
  • MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

The Company is headquartered in Woonsocket, Rhode Island.

Check MCET Stock Information

Investor Relations
(401) 762-0045
Email: mcetinvestor@aol.com

Transfer Agent:

Corporate Stock Transfer, Inc.
3200 Cherry Creek South Drive, Suite  430
Denver, CO.  80209
W:  303-282-4800
F:  303-282-5800